Show simple item record

dc.contributorTansey EM
dc.contributorBlackburn T
dc.contributor.advisorTansey EM
dc.contributor.advisorZarros A
dc.contributor.otherGee D
dc.contributor.otherYabsley A
dc.contributor.otherWilkinson A
dc.date.accessioned2016-06-30T13:13:41Z
dc.date.available2016-06-30T13:13:41Z
dc.date.issued30/06/2016
dc.date.submitted2016-06-22T10:58:40.321Z
dc.date.submitted2016-06-30T13:23:32.473Z
dc.identifier.urihttp://qmro.qmul.ac.uk/xmlui/handle/123456789/13141
dc.description.abstractInterview with Dr Tom Blackburn, conducted by Professor Tilli Tansey, for the History of Modern Biomedicine Research Group, 22 February 2016, in the School of History, Queen Mary University of London. Transcribed by Mrs Debra Gee, and edited by Professor Tilli Tansey and Dr Apostolos Zarros. The project management and the technical support were undertaken by Mr Adam Wilkinson and Mr Alan Yabsley, respectively. Dr Tom Blackburn CBiol MIBiol MPhil PhD DSc HonFBPhS (b. 1949) received his degrees from Nottingham and Manchester Universities. He has held C-level executive and senior management positions at ICI Pharmaceuticals plc, Beecham Pharmaceuticals plc and SmithKline Beecham in the UK, and with two biotech companies in the US, Synaptic Pharmaceutical Corporation and Helicon Therapeutics Inc. He has led companies, departments, and project teams that identified and developed novel therapeutics, including several serotonin receptor subtype antagonists (5-HT2A, 5-HT2B, 5-HT2C and 5-HT3), galanin receptor 3 antagonist and the selective serotonin reuptake inhibitor (SSRI) antidepressant, Seroxat/Paxil. His passion, based on an extensive knowledge of pre-clinical/clinical drug development and marketing, helps to define strategies and positioning of pharmaceutical products for biotech startup companies. He is currently Founder and CEO of TPBioVentures LLC, a ‘virtual’ drug development and consultancy company in the US and UK. He has authored over 100 peer reviewed scientific papers, review articles and book chapters and is an inventor on 22 patents. He is President Emeritus of the British Pharmacological Society and a Member of the American College of Neuropsychopharmacology. He is also a Non-Executive Director for Motac Neuroscience Ltd., a neuroscience biotechnology company specializing in Parkinson’s disease and cognitive and neurodegenerative disorders.en_US
dc.description.sponsorshipThe History of Modern Biomedicine Research Group is funded by the Wellcome Trust, which is a registered charity (no. 210183). The current interview has been funded by the Wellcome Trust Strategic Award entitled “Makers of modern biomedicine: testimonies and legacy” (2012-2017; awarded to Professor Tilli Tansey).en_US
dc.language.isoenen_US
dc.relation.ispartofseriesHistory of Modern Biomedicine Interviews (Digital Collection);e2016045
dc.rightsAttribution 3.0 United States
dc.rights.urihttp://creativecommons.org/licenses/by/3.0/us/
dc.subjectHistory of Modern Biomedicine Research Groupen_US
dc.subjectAudio Interviewen_US
dc.subjectDrugs and Pharmacologistsen_US
dc.subjectNervous System and Neuroscientistsen_US
dc.titleBlackburn, Tom: transcript of an audio interview (22-Feb-2016)en_US
dc.typeOtheren_US
dc.identifier.doi10.17636/01013141


Files in this item

Thumbnail
Thumbnail

This item appears in the following Collection(s)

Show simple item record

Attribution 3.0 United States
Except where otherwise noted, this item's license is described as Attribution 3.0 United States